Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:2)
2. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrochloride (1:1)
3. E 7438
4. E-7438 Hydrobromide
5. E7438
6. Epz-6438
7. Epz-6438 Dihydrobromide
8. Epz-6438 Monohydrobromide
9. Epz-6438 Monohydrochloride
10. Epz-6438 Trihydrochloride
11. Ez-438
12. Ez438
13. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide
14. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide
15. Tazemetostat
16. Tazemetostat Dihydrobromide
17. Tazemetostat Hydrochloride
18. Tazemetostat Monohydrobromide
19. Tazemetostat Monohydrochloride
20. Tazemetostat Trihydrochloride
21. Tazverik
1. 1467052-75-0
2. Tazemetostat Monohydrobromide
3. Epz-6438 Monohydrobromide
4. E-7438 Hydrobromide
5. Ez438
6. Tazemetostat (hydrobromide)
7. Epz-6438 Hydrobromide
8. Tazemetostat Hydrobromide [usan]
9. Tazverik
10. Ez-438
11. 6p89t5m073
12. (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, Hydrobromide (1:1)
13. N-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide
14. Unii-6p89t5m073
15. Tazverik (tn)
16. 1467052-77-2
17. Chembl4594260
18. Schembl15313373
19. Dtxsid101027715
20. Hy-13803c
21. Tazemetostat Hydrobromide (jan/usan)
22. Tazemetostat Hydrobromide [jan]
23. Tazemetostat Hydrobromide [who-dd]
24. Epz-6438 Hydrobromide; Tazemetostat Hbr
25. Cs-0101826
26. D11485
27. Tazemetostat Hydrobromide [orange Book]
28. Q27265267
29. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide Monohydrobromide
30. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide Hydrobromide
31. N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamidehydrobromide
Molecular Weight | 653.6 g/mol |
---|---|
Molecular Formula | C34H45BrN4O4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 9 |
Exact Mass | 652.26242 g/mol |
Monoisotopic Mass | 652.26242 g/mol |
Topological Polar Surface Area | 83.1 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 992 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
NDC Package Code : 50384-4000
Start Marketing Date : 2020-01-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (160kg/160kg)
Marketing Category : BULK INGREDIENT
Details:
Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is indicated for the treatment of relapsed or refractory follicular lymphoma.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2025
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Wins NMPA Nod for Tazemetostat in R/R Follicular Lymphoma
Details : Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is indicated for the treatment of relapsed or refractory follicular lymphoma.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2025
Details:
Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is being evaluated for the treatment of relapsed or refractory follicular lymphoma.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 07, 2024
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Receives NDA Acceptance & Priority Review for Tazemetostat in Follicular Lymphoma
Details : Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is being evaluated for the treatment of relapsed or refractory follicular lymphoma.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2024
Details:
TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of relapsed/refractory follicular lymphoma.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2023
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of relapsed/refractory follicular lymphoma.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Details:
Eisai will provide Tazverik free of charge to the National Cancer Center Hospital as the drug to be used in a clinical trial of Tazemetostat, a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2, for pediatric and AYA patients with malignant tumors.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: National Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 04, 2023
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : National Cancer Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : Eisai will provide Tazverik free of charge to the National Cancer Center Hospital as the drug to be used in a clinical trial of Tazemetostat, a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2, for pediatric and AYA patients wi...
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 04, 2023
Details:
Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-inclass, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Ipsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 08, 2022
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Ipsen
Deal Size : Undisclosed
Deal Type : Acquisition
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
Details : Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-inclass, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 08, 2022
Details:
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2[1] inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Ipsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 27, 2022
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Ipsen
Deal Size : Undisclosed
Deal Type : Acquisition
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
Details : The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2[1] inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 27, 2022
Details:
First patient dosed in the randomized portion of symphony-1 (EZH-302), epizyme’s phase 1B/3 confirmatory study of Tazverik (tazemetostat) in combination with rituximab + lenalidomide (R2) for the treatment of follicular lymphoma.
Lead Product(s): Tazemetostat,Lenalidomide,Rituximab
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 15, 2022
Lead Product(s) : Tazemetostat,Lenalidomide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
Details : First patient dosed in the randomized portion of symphony-1 (EZH-302), epizyme’s phase 1B/3 confirmatory study of Tazverik (tazemetostat) in combination with rituximab + lenalidomide (R2) for the treatment of follicular lymphoma.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2022
Details:
Treatment with Tazverik (tazemetostat) and R2 was generally well tolerated and the adverse events were consistent with those contained in the prescribing information for both tazemetostat and R2, respectively.
Lead Product(s): Tazemetostat,Lenalidomide,Rituximab
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2022
Lead Product(s) : Tazemetostat,Lenalidomide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment with Tazverik (tazemetostat) and R2 was generally well tolerated and the adverse events were consistent with those contained in the prescribing information for both tazemetostat and R2, respectively.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2022
Details:
Epizyme anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund global development and commercialization costs of tazemetostat outside of Japan.
Lead Product(s): Tazemetostat,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Jefferies
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 27, 2022
Lead Product(s) : Tazemetostat,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies
Deal Size : $85.0 million
Deal Type : Public Offering
Epizyme Announces Pricing of Public Offering of Common Stock
Details : Epizyme anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund global development and commercialization costs of tazemetostat outside of Japan.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 27, 2022
Details:
TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Brand Name: Tazverik
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2022
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resecti...
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2022
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
80
PharmaCompass offers a list of Tazemetostat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tazemetostat manufacturer or Tazemetostat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tazemetostat manufacturer or Tazemetostat supplier.
PharmaCompass also assists you with knowing the Tazemetostat API Price utilized in the formulation of products. Tazemetostat API Price is not always fixed or binding as the Tazemetostat Price is obtained through a variety of data sources. The Tazemetostat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tazemetostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tazemetostat, including repackagers and relabelers. The FDA regulates Tazemetostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tazemetostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tazemetostat supplier is an individual or a company that provides Tazemetostat active pharmaceutical ingredient (API) or Tazemetostat finished formulations upon request. The Tazemetostat suppliers may include Tazemetostat API manufacturers, exporters, distributors and traders.
click here to find a list of Tazemetostat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tazemetostat as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tazemetostat API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tazemetostat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tazemetostat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tazemetostat NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tazemetostat suppliers with NDC on PharmaCompass.
Tazemetostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tazemetostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tazemetostat GMP manufacturer or Tazemetostat GMP API supplier for your needs.
A Tazemetostat CoA (Certificate of Analysis) is a formal document that attests to Tazemetostat's compliance with Tazemetostat specifications and serves as a tool for batch-level quality control.
Tazemetostat CoA mostly includes findings from lab analyses of a specific batch. For each Tazemetostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tazemetostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Tazemetostat EP), Tazemetostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tazemetostat USP).